Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial
J Hiremath, S Thanikachalam, K Parikh… - The Journal of heart and …, 2010 - Elsevier
BACKGROUND: Pulmonary arterial hypertension (PAH) remains a poorly understood and
frequently lethal disease with few treatment options. METHODS: We conducted a placebo …
frequently lethal disease with few treatment options. METHODS: We conducted a placebo …
Management strategies for patients with pulmonary hypertension in the intensive care unit
RT Zamanian, F Haddad, RL Doyle… - Critical care …, 2007 - journals.lww.com
Objective: Pulmonary hypertension may be encountered in the intensive care unit in patients
with critical illnesses such as acute respiratory distress syndrome, left ventricular …
with critical illnesses such as acute respiratory distress syndrome, left ventricular …
Autoimmunity and pulmonary hypertension: a perspective
MR Nicolls, L Taraseviciene-Stewart… - European …, 2005 - Eur Respiratory Soc
The association between autoimmunity and pulmonary arterial hypertension (PAH) has
been appreciated for> 40 yrs, but how autoimmune injury might contribute to the …
been appreciated for> 40 yrs, but how autoimmune injury might contribute to the …
TRPC6, a therapeutic target for pulmonary hypertension
PP Jain, N Lai, M Xiong, J Chen… - … of Physiology-Lung …, 2021 - journals.physiology.org
Idiopathic pulmonary arterial hypertension (PAH) is a fatal and progressive disease.
Sustained vasoconstriction due to pulmonary arterial smooth muscle cell (PASMC) …
Sustained vasoconstriction due to pulmonary arterial smooth muscle cell (PASMC) …
Contribution of inflammation and impaired angiogenesis to the pathobiology of chronic thromboembolic pulmonary hypertension
R Quarck, M Wynants, E Verbeken… - European …, 2015 - Eur Respiratory Soc
Deficient angiogenesis and systemic inflammation could be involved in the pathophysiology
of chronic thromboembolic pulmonary hypertension (CTEPH). We aimed to characterise the …
of chronic thromboembolic pulmonary hypertension (CTEPH). We aimed to characterise the …
[HTML][HTML] Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents
M Izikki, C Guignabert, E Fadel… - The Journal of …, 2009 - Am Soc Clin Investig
Pulmonary hypertension (PH) is a progressive, lethal lung disease characterized by
pulmonary artery SMC (PA-SMC) hyperplasia leading to right-sided heart failure. Molecular …
pulmonary artery SMC (PA-SMC) hyperplasia leading to right-sided heart failure. Molecular …
Role of endothelium-derived CC chemokine ligand 2 in idiopathic pulmonary arterial hypertension
O Sanchez, E Marcos, F Perros, E Fadel… - American journal of …, 2007 - atsjournals.org
Rationale: Inflammatory cytokines may affect pulmonary vascular remodeling in idiopathic
pulmonary arterial hypertension (IPAH). CC chemokine ligand 2 (CCL2) is synthesized by …
pulmonary arterial hypertension (IPAH). CC chemokine ligand 2 (CCL2) is synthesized by …
Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling
R Dumitrascu, N Weissmann, HA Ghofrani, E Dony… - Circulation, 2006 - Am Heart Assoc
Background—Severe pulmonary hypertension is a disabling disease with high mortality,
characterized by pulmonary vascular remodeling and right heart hypertrophy. Using wild …
characterized by pulmonary vascular remodeling and right heart hypertrophy. Using wild …
[HTML][HTML] Management of pulmonary arterial hypertension
JD Mayeux, IZ Pan, J Dechand, JA Jacobs… - Current cardiovascular …, 2021 - Springer
Abstract Purpose of Review This review focuses on the therapeutic management and
individualized approach to Group 1 pulmonary arterial hypertension (PAH), utilizing Food …
individualized approach to Group 1 pulmonary arterial hypertension (PAH), utilizing Food …
[HTML][HTML] Bone morphogenetic protein 2 induces pulmonary angiogenesis via Wnt–β-catenin and Wnt–RhoA–Rac1 pathways
VA de Jesus Perez, TP Alastalo, JC Wu… - The Journal of cell …, 2009 - ncbi.nlm.nih.gov
Mutations in bone morphogenetic protein (BMP) receptor II (BMPRII) are associated with
pulmonary artery endothelial cell (PAEC) apoptosis and the loss of small vessels seen in …
pulmonary artery endothelial cell (PAEC) apoptosis and the loss of small vessels seen in …